Eyepoint Pharmaceuticals Stock Price To Sales

EYPT Stock

USD 6.63 0.11 1.69%

Eyepoint Pharmaceuticals fundamentals help investors to digest information that contributes to Eyepoint Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eyepoint Stock. The fundamental analysis module provides a way to measure Eyepoint Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eyepoint Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	9.69	9.21

Price To Sales Ratio is likely to drop to 9.21 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Eyepoint Pharmaceuticals Company Price To Sales Analysis

Eyepoint Pharmaceuticals' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Eyepoint Pharmaceuticals Price To Sales

10.36 X

Most of Eyepoint Pharmaceuticals' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eyepoint Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Eyepoint Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Eyepoint Pharmaceuticals is extremely important. It helps to project a fair market value of Eyepoint Stock properly, considering its historical fundamentals such as Price To Sales. Since Eyepoint Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eyepoint Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eyepoint Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Accounts Payable	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Term Debt	Short Term Investments	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Long Term Debt Total	Short Long Term Debt	Capital Stock
Total Assets		0.99	-0.71	-0.92	0.16	0.82	1.0	0.5	-0.19	0.8	0.8	-0.21	0.65	-0.23	0.85	0.85	0.79	0.4	1.0	1.0	0.58	-0.72	-0.69
Total Stockholder Equity	0.99		-0.7	-0.86	0.04	0.7	0.99	0.37	-0.31	0.72	0.76	-0.17	0.54	-0.19	0.89	0.84	0.71	0.3	0.98	0.99	0.47	-0.6	-0.61
Net Debt	-0.71	-0.7		0.6	-0.11	-0.58	-0.74	-0.33	0.15	-0.35	-0.73	0.14	-0.35	0.16	-0.31	-0.73	-0.67	-0.25	-0.7	-0.72	-0.26	0.47	0.55
Retained Earnings	-0.92	-0.86	0.6		-0.32	-0.9	-0.91	-0.6	-0.04	-0.84	-0.76	0.46	-0.77	0.47	-0.75	-0.74	-0.86	-0.57	-0.91	-0.9	-0.69	0.83	0.75
Net Receivables	0.16	0.04	-0.11	-0.32		0.53	0.14	0.5	0.84	0.37	0.6	-0.17	0.62	-0.17	-0.13	0.38	0.52	0.42	0.16	0.14	0.67	-0.54	-0.59
Total Liab	0.82	0.7	-0.58	-0.9	0.53		0.79	0.82	0.25	0.88	0.77	-0.3	0.89	-0.31	0.53	0.68	0.87	0.65	0.8	0.78	0.8	-0.98	-0.82
Total Current Assets	1.0	0.99	-0.74	-0.91	0.14	0.79		0.45	-0.21	0.76	0.81	-0.2	0.62	-0.22	0.84	0.86	0.78	0.37	0.99	1.0	0.54	-0.69	-0.69
Intangible Assets	0.5	0.37	-0.33	-0.6	0.5	0.82	0.45		0.35	0.73	0.49	-0.27	0.75	-0.29	0.24	0.35	0.62	0.58	0.48	0.44	0.68	-0.87	-0.55
Common Stock	-0.19	-0.31	0.15	-0.04	0.84	0.25	-0.21	0.35		0.06	0.28	-0.31	0.32	-0.3	-0.4	0.06	0.25	0.34	-0.19	-0.21	0.32	-0.28	-0.32
Accounts Payable	0.8	0.72	-0.35	-0.84	0.37	0.88	0.76	0.73	0.06		0.6	-0.24	0.88	-0.26	0.69	0.56	0.71	0.6	0.8	0.76	0.83	-0.89	-0.55
Property Plant Equipment	0.8	0.76	-0.73	-0.76	0.6	0.77	0.81	0.49	0.28	0.6		-0.18	0.64	-0.19	0.49	0.95	0.83	0.41	0.81	0.81	0.58	-0.68	-0.81
Current Deferred Revenue	-0.21	-0.17	0.14	0.46	-0.17	-0.3	-0.2	-0.27	-0.31	-0.24	-0.18		-0.22	1.0	-0.12	-0.13	-0.25	-0.29	-0.18	-0.16	-0.21	0.25	0.19
Long Term Debt	0.65	0.54	-0.35	-0.77	0.62	0.89	0.62	0.75	0.32	0.88	0.64	-0.22		-0.24	0.42	0.45	0.76	0.79	0.66	0.62	0.94	-0.91	-0.71
Short Term Debt	-0.23	-0.19	0.16	0.47	-0.17	-0.31	-0.22	-0.29	-0.3	-0.26	-0.19	1.0	-0.24		-0.13	-0.15	-0.26	-0.3	-0.2	-0.18	-0.22	0.27	0.2
Short Term Investments	0.85	0.89	-0.31	-0.75	-0.13	0.53	0.84	0.24	-0.4	0.69	0.49	-0.12	0.42	-0.13		0.63	0.49	0.18	0.86	0.85	0.37	-0.46	-0.42
Net Tangible Assets	0.85	0.84	-0.73	-0.74	0.38	0.68	0.86	0.35	0.06	0.56	0.95	-0.13	0.45	-0.15	0.63		0.76	0.22	0.86	0.87	0.4	-0.57	-0.69
Capital Surpluse	0.79	0.71	-0.67	-0.86	0.52	0.87	0.78	0.62	0.25	0.71	0.83	-0.25	0.76	-0.26	0.49	0.76		0.65	0.78	0.78	0.65	-0.85	-0.75
Deferred Long Term Liab	0.4	0.3	-0.25	-0.57	0.42	0.65	0.37	0.58	0.34	0.6	0.41	-0.29	0.79	-0.3	0.18	0.22	0.65		0.42	0.38	0.58	-0.71	-0.47
Net Invested Capital	1.0	0.98	-0.7	-0.91	0.16	0.8	0.99	0.48	-0.19	0.8	0.81	-0.18	0.66	-0.2	0.86	0.86	0.78	0.42		1.0	0.57	-0.72	-0.68
Net Working Capital	1.0	0.99	-0.72	-0.9	0.14	0.78	1.0	0.44	-0.21	0.76	0.81	-0.16	0.62	-0.18	0.85	0.87	0.78	0.38	1.0		0.54	-0.68	-0.68
Long Term Debt Total	0.58	0.47	-0.26	-0.69	0.67	0.8	0.54	0.68	0.32	0.83	0.58	-0.21	0.94	-0.22	0.37	0.4	0.65	0.58	0.57	0.54		-0.81	-0.65
Short Long Term Debt	-0.72	-0.6	0.47	0.83	-0.54	-0.98	-0.69	-0.87	-0.28	-0.89	-0.68	0.25	-0.91	0.27	-0.46	-0.57	-0.85	-0.71	-0.72	-0.68	-0.81		0.73
Capital Stock	-0.69	-0.61	0.55	0.75	-0.59	-0.82	-0.69	-0.55	-0.32	-0.55	-0.81	0.19	-0.71	0.2	-0.42	-0.69	-0.75	-0.47	-0.68	-0.68	-0.65	0.73

Click cells to compare fundamentals

Eyepoint Price To Sales Historical Pattern

Today, most investors in Eyepoint Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eyepoint Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Eyepoint Pharmaceuticals price to sales as a starting point in their analysis.

Eyepoint Pharmaceuticals Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Eyepoint Pharmaceuticals

Price To Sales Ratio Over Time

Eyepoint Price To Sales Ratio

Price To Sales Ratio

9.21

At this time, Eyepoint Pharmaceuticals' Price To Sales Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, Eyepoint Pharmaceuticals has a Price To Sales of 10.3555 times. This is 51.61% lower than that of the Pharmaceuticals sector and 89.48% lower than that of the Health Care industry. The price to sales for all United States stocks is 9.32% higher than that of the company.

Eyepoint Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eyepoint Pharmaceuticals' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eyepoint Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eyepoint Pharmaceuticals by comparing valuation metrics of similar companies.

Eyepoint Pharmaceuticals is currently under evaluation in price to sales category among its peers.

Eyepoint Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eyepoint Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eyepoint Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Eyepoint Fundamentals

	Return On Equity	-0.43
	Return On Asset	-0.24
	Operating Margin	(3.90) %
	Current Valuation	99.06 M
	Shares Outstanding	68.73 M
	Shares Owned By Insiders	1.13 %
	Shares Owned By Institutions	98.87 %
	Number Of Shares Shorted	11.09 M
	Price To Earning	(2.82) X
	Price To Book	1.33 X
	Price To Sales	10.36 X
	Revenue	43.27 M
	Gross Profit	21.09 M
	EBITDA	(129.23 M)
	Net Income	(130.87 M)
	Cash And Equivalents	171.17 M
	Cash Per Share	5.02 X
	Total Debt	21.86 M
	Debt To Equity	0.30 %
	Current Ratio	6.16 X
	Book Value Per Share	4.93 X
	Cash Flow From Operations	(126.23 M)
	Short Ratio	11.92 X
	Earnings Per Share	(2.32) X
	Target Price	33.0
	Number Of Employees	165
	Beta	1.42
	Market Capitalization	448.11 M
	Total Asset	418.46 M
	Retained Earnings	(873.02 M)
	Working Capital	334.26 M
	Current Asset	15.08 M
	Current Liabilities	11.26 M
	Net Asset	418.46 M

About Eyepoint Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Eyepoint Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eyepoint Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eyepoint Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC